Le Lézard

Communiqués de presse par sujet : Essais cliniques / Découvertes médicales

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

2 août 2018

07:00
ArmaGen, Inc., a privately held biotechnology company focused on developing groundbreaking therapies to treat severe neurological disorders, today announced that the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development...


1 août 2018

19:27
CalciMedica announced that the first patients in a Phase 2a clinical study for acute pancreatitis have been dosed with its proprietary calcium release-activated calcium (CRAC) channel inhibitor CM4620. The study is intended to provide safety and...

16:45
Mallinckrodt plc , a leading global specialty pharmaceutical company, today announced it has initiated a company-sponsored, experimental, proof-of-concept study of nitric oxide gas with ex-vivo lung perfusion compared to lung perfusion alone in human...

15:27
Baker's yeast survive and grow after a drastic reorganization, not of their genes, but of the chromosome superstructures that house, protect and control access to their DNA code, a study just published in Nature finds.  ...

13:33
Lenox Hill Hospital and The Feinstein Institute for Medical Research have been chosen as study site to identify biomarkers for focal seizures in patients with treatment-resistant epilepsy. Researchers hope the study, called Human Epilepsy Project...

10:00
Vascular Graft Solutions announces today that John Radcliffe hospital in Oxford, is the first center in the UK to use its VEST technology to externally support vein grafts in patients undergoing coronary bypass surgery....

09:47
Chemically coated, ceramic implants successfully guided the regrowth of missing bone in lab animals while "steadily dissolving," researchers report.   Surgeons and scientists at NYU School of Medicine and NYU College of...

09:25
RXi Pharmaceuticals Corporation a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA) therapeutic platform, today announced positive results with RXI-109 in a...

09:03
Wills Eye Hospital has been given Food and Drug Administration (FDA) approval to begin an early feasibility study (EFS) to implant the RETINA IMPLANT Alpha AMS sub-retinal device in patients blind due to Retinitis Pigmentosa (RP). The Alpha AMS is...

08:30
OWC Pharmaceutical Research Corp. , a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, announced today the initiation of the final stage of its Phase I, placebo controlled, maximal dose study...

07:30
Imprimis Pharmaceuticals, Inc. through its ImprimisRx ophthalmology business today announced its Canadian partner, Advanced Dosage Forms Inc., will begin enrolling patients at McGill University Health Centre (MUHC) for a clinical trial of Imprimis's...

07:16
Cantargia AB announce that the Chinese patent authority, State Intellectual Property Office ("SIPO") has issued a formal approval concerning the company's patent application of the immuno-oncological antibody CAN04 (nidanilimab). CAN04 binds...

07:00
ITUS Corporation today announced that it and its research partner, Moffitt Cancer Center, have requested a meeting with the US FDA to review the plan for advancing their CAR-T therapy for Ovarian Cancer into human clinical trials.  ...

07:00
Theravance Biopharma, Inc. ("Theravance Biopharma") today announced positive four-week results from a Phase 2 clinical trial of TD-9855, an investigational, once-daily norepinephrine and serotonin reuptake inhibitor (NSRI) in development for the...

07:00
BioLineRx Ltd. , a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it has initiated a Phase 1/2a clinical study for AGI-134, a novel compound that evokes a direct anti-tumor response, as well as a...

03:00
Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven" or the "Company") announced today that it has enrolled the first patient in a Phase 2/3 clinical trial of trigriluzole (BHV-4157), a novel glutamate modulator for the treatment of...


31 juillet 2018

19:01
Owen Mumford, pioneers of safety lancets for capillary blood sampling, is supporting healthcare professionals gain confidence and achieve better samples as a result When used correctly, POCT has been shown to improve patient care and work flow...

18:30
Laekna Inc., a biotechnology company headquartered in Shanghai, announced today the signing of an agreement with Novartis Pharma AG for exclusive global rights to develop and commercialize two oral Novartis clinical-stage oncology assets. The...

16:01
Sangamo Therapeutics, Inc. announced today that preliminary safety and efficacy data from the CHAMPIONS Study, a Phase 1/2 clinical trial evaluating SB-913 for the treatment of mucopolysaccharidosis Type II (MPS II, also known as Hunter syndrome),...

15:21
XpertDox, a data analytics firm focused on improving healthcare outcomes for patients with serious and rare diseases, today announced that the University of Alabama at Birmingham (UAB), one of the largest academic medical centers in the United...

10:30
Researchers have developed a novel test that rapidly distinguishes between type 1 and type 2 diabetes. This new method and a second study revealing gaps in care for women with gestational diabetes were presented today at the 70th AACC Annual...

10:25
A rope coiled on dusty trail may trigger a frightened jump by hiker who recently stepped on a snake. Now a new study better explains how a one-time visual experience can shape perceptions afterward. Led by...

09:15
BioPharmX Corporation , a specialty pharmaceutical company developing products for the dermatology market, today announced it has received Institutional Review Board approval for its phase 2 study of BPX-04 for the treatment of papulopustular...

09:00
RadiaDyne, the designer and manufacturer of the market leading Endorectal Balloon device utilized during radiation therapy for prostate cancer, announced today a pivotal published study utilizing their technology.  The study evaluated proton therapy...

08:31
Ascletis announced today that it has filed the new drug application (NDA) for its second Category 1 HCV drug - Ravidasvir (RDV, ASC16). The company expects to receive feedback from the China Food and Drug Administration (CFDA) within five business...

08:00
Eiger BioPharmaceuticals, Inc. , focused on the development and commercialization of targeted therapies for rare diseases, announced today that it has received the Notice of Allowance from the United States Patent and Trademark Office (USPTO) for...

08:00
The TIGERTRIEVER 13 is the smallest profile stentriever, designed to safely retrieve clots from intracranial vessels of 1mm - 2.5mm.  Rapid Medical, a company focused on the development of next generation neurovascular devices, has announced that it...

08:00
Audentes Therapeutics, Inc. , a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, will host a conference call and webcast to report its...

08:00
ReShape Lifesciences Inc. , a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today the Company has commenced site initiation training for the first clinical trial site that will participate in the...

08:00
Le TIGERTRIEVER 13 est le stentriever qui présente le profil le plus petit et est conçu pour extraire en toute sécurité les caillots des vaisseaux intracrâniens mesurant entre 1 mm et 2,5 mm  Rapid Medical, une société spécialisée dans le...

06:00
United Therapeutics Corporation today announced approval by the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) for the use of Remodulin (treprostinil) Injection in the Implantable System for Remodulin® (ISR). The ISR has...

05:34
L'étude ATLANTIS sur le traitement du cancer du poumon à petites cellules à la lurbinectine a recruté 600 patients dans un total de 160 centres hospitaliers de 20 pays  Les données principales devraient être disponibles vers la fin de 2019 ...

05:25
ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160 hospital centers in 20 countries   Top line data is expected to readout around the end of 2019    PharmaMar (MCE: PHM) has today announced that...

03:00
Released today, a new report based on research by the Economist Intelligence Unit (EIU) and sponsored by Pfizer Vaccines assesses why, despite the evidence supporting the medical and cost-saving benefits of preventative healthcare measures, consumers...


30 juillet 2018

14:00
The FH Foundation announced that an important consensus statement on diagnosing familial hypercholesterolemia (FH), a common life-threatening genetic condition, was published online today in the Journal of the American College of Cardiology. Authored...

09:49
Neurim Pharmaceuticals ("Neurim") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorization for Slenyto®, a pediatric...

09:15
Nektar Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has filed and accepted for review the company's New Drug Application (NDA) for NKTR-181 for the treatment of chronic low back pain in adult patients new to opioid...

09:00
DURHAM, N.C., July 30, 2018 /PRNewswire-PRWeb/ -- A new type of stem cell treatment is showing promise for patients undergoing hemodialysis (HD) who suffer from critical limb ischemia (CLI). Results of a clinical trial, reported on in a recently...

08:30
Cerapedics, a privately-held orthobiologics company, today announced that the first patients have been enrolled in an investigational device exemption (IDE) clinical trial evaluating the safety and efficacy of the next-generation P-15L Peptide...

07:30
IFM Therapeutics, LLC (IFM), a privately held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, today announced the publication of a comprehensive review of current knowledge on NLRP3...

07:11
Presbyopia Therapies, LLC, a privately-held ophthalmic pharmaceutical company dedicated to developing therapies for the treatment of presbyopia, today announced that the primary efficacy and safety endpoints have been met in a Phase IIb study of its...

07:00
BioLineRx Ltd. , a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today the expansion of its immuno-oncology collaboration with Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside the United States...

07:00
ITUS Corporation today announced that it has released interim data from a breast cancer study using its Cchektm non-invasive (utilizing a blood sample), artificial intelligence (AI) guided, liquid biopsy cancer detection platform, that showed...

06:30
Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced that the University of Arizona Cancer Center (UACC) and its clinical partner Banner ? University Medical Center...

06:00
Nucleix Ltd., a leading cancer detection and screening company, announced today that it has received ?2.5 million in funding, following its application to the highly-selective EIC pilot SME Instrument Phase 2 European programme. EIC pilot SME...

04:55
Chesapeake Research Group, CRG, is currently enrolling patients in a clinical research study for an investigational medication used to treat post-operative pain. The new medication could help combat America's opioid epidemic. America's opioid...


29 juillet 2018

22:21
Foresee Pharmaceuticals Co., Ltd. (6576.TWO) (« Foresee »), a annoncé aujourd'hui avoir conclu avec succès un essai clinique de phase 1 à dose ascendante multiple portant sur le FP-045, une petite molécule orale puissante et activatrice de l'ALDH2,...


27 juillet 2018

08:30
Curis, Inc. , a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the Company will release its second quarter 2018 financial results...

06:45
Le premier essai clinique randomisé, qui a démontré que le traitement intensif de la pression artérielle réduit les nouveaux cas de troubles légers de la cognition (TLC) et le risque combiné de TLC et de démence toutes causes confondues, a été le...

01:49
Medivir AB today announces positive top-line joint structure outcomes from the MIV-711 osteoarthritis phase IIa extension study (MIV-711-202). Treatment with MIV-711 over a total 12 months resulted in a continuing treatment effect on joint bone area...

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19